CYPH
CypherpunkCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
Bull case is that the compliance overhang is gone, the company has kept expanding its ZEC treasury and ZODL exposure, and sirexatamab now has an FDA Fast Track designation that helps preserve oncology option value [#8-K-2026-05-26] [#SEC-8K-2026-05-14].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Fast Track designation helps, but sirexatamab still faces clinical, regulatory, and eventual commercialization risk [#SEC-8K-2026-05-14].
Momentum
79
Value
44
Sentiment
38
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.68 · Bull $1.05 · Bear $0.27
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-06 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $0.90
Why
Momentum79 · Δ7d -
Value44 · Δ7d -0.0
Sentiment38 · Δ7d -
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
79
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
44
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.1
Sentiment
38
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade C. Momentum 78.7 / Value 44.1 / Sentiment 38.3
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$75.39M
Beta
-0.19
Shares Out
106.46M
P/E (TTM) · Derived
9.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.98
Rev YoY
-100.0%
EPS YoY
+22.7%
Gross Margin
-
Op Margin
-
Net Debt
-$14M
Current Ratio
27.28
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology